Chemomab Therapeutics Ltd
CMMB2.640USD
-0.030-1.12%
取引時間 （ET）15分遅れの株価
13.66M時価総額
損失額直近12ヶ月PER
詳細情報 Chemomab Therapeutics Ltd 企業名
Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.
Chemomab Therapeutics Ltdの企業情報
企業コードCMMB
会社名Chemomab Therapeutics Ltd
上場日Aug 14, 2012
最高経営責任者「CEO」Dr. Adi Mor, Ph.D.
従業員数16
証券種類Depository Receipt
決算期末Aug 14
本社所在地Kiryat Atidim, Building 7
都市TEL AVIV-YAFO
証券取引所NASDAQ Capital Market Consolidated
国Israel
郵便番号6158002
電話番号972773310156
ウェブサイトhttps://www.chemomab.com/
企業コードCMMB
上場日Aug 14, 2012
最高経営責任者「CEO」Dr. Adi Mor, Ph.D.
Chemomab Therapeutics Ltdの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
639.00
-82.96%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
Dr. Adi Mor, Ph.D.
Dr. Adi Mor, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Jack Lawler
Mr. Jack Lawler
Chief Development Officer
Chief Development Officer
--
--
Dr. David M. Weiner, M.D.
Dr. David M. Weiner, M.D.
Interim Chief Medical Officer
Interim Chief Medical Officer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Sigal Fattal, CPA
Ms. Sigal Fattal, CPA
Chief Financial Officer
Chief Financial Officer
639.00
-82.96%
Dr. Nissim Darvish, M.D. Ph.D.
Dr. Nissim Darvish, M.D. Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
300.00
--
Mr. Neil Cohen
Mr. Neil Cohen
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ms. Irina Koffler
Ms. Irina Koffler
Investor Relations
Investor Relations
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Tue, Oct 28
更新時刻: Tue, Oct 28
株主統計
種類
株主統計
株主統計
比率
Otto (Erik)
8.17%
Morgan Stanley & Co. LLC
7.80%
Apeiron Investment Group Ltd
5.47%
Rivendell Investments 2017-9 LLC
5.36%
OrbiMed Advisors, LLC
4.55%
他の
68.66%
株主統計
株主統計
比率
Otto (Erik)
8.17%
Morgan Stanley & Co. LLC
7.80%
Apeiron Investment Group Ltd
5.47%
Rivendell Investments 2017-9 LLC
5.36%
OrbiMed Advisors, LLC
4.55%
他の
68.66%
種類
株主統計
比率
Individual Investor
11.37%
Research Firm
7.97%
Family Office
5.47%
Corporation
5.36%
Hedge Fund
4.60%
Private Equity
4.55%
Investment Advisor
0.35%
Investment Advisor/Hedge Fund
0.14%
他の
60.20%
機関投資家保有株
更新時刻: Wed, Oct 1
更新時刻: Wed, Oct 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q3
29
910.59K
17.60%
-52.42K
2025Q2
36
5.04M
26.29%
-928.14K
2025Q1
38
6.66M
34.89%
+231.83K
2024Q4
41
7.89M
41.83%
+519.06K
2024Q3
37
7.12M
38.75%
+430.17K
2024Q2
36
5.24M
33.24%
-261.90K
2024Q1
39
5.24M
33.39%
-405.62K
2023Q4
41
5.39M
34.50%
+2.72K
2023Q3
43
5.63M
49.23%
-777.20K
2023Q2
42
5.63M
49.23%
-912.41K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Otto (Erik)
422.50K
8.17%
+133.75K
+46.32%
Aug 11, 2025
Morgan Stanley & Co. LLC
403.53K
7.8%
+374.24K
+1277.72%
Jun 30, 2025
Apeiron Investment Group Ltd
283.00K
5.47%
+101.21K
+55.68%
Dec 31, 2024
Rivendell Investments 2017-9 LLC
277.13K
5.36%
--
--
Dec 31, 2024
OrbiMed Advisors, LLC
235.25K
4.55%
-200.07K
-45.96%
Jun 30, 2025
Sphera Funds Management Ltd.
184.51K
3.57%
-40.59K
-18.03%
Jun 30, 2025
Mor George (Adi)
79.27K
1.53%
--
--
Dec 31, 2024
Ikarian Capital LLC
53.26K
1.03%
--
--
Jun 30, 2025
George (Kobi)
50.06K
0.97%
-12.73K
-20.27%
Dec 31, 2024
Cohen (Neil Harris)
35.30K
0.68%
-2.50K
-6.61%
Dec 31, 2024
詳細を見る
関連ETF
銘柄名
比率
データなし
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
日付
種類
比率
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
Mar 16, 2021
Merger
16→1
